Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) EBIT Margin (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed EBIT Margin for 6 consecutive years, with 114.97% as the latest value for Q3 2025.

  • For Q3 2025, EBIT Margin rose 46647.0% year-over-year to 114.97%; the TTM value through Sep 2025 reached 127.25%, up 292687.0%, while the annual FY2024 figure was 181.4%, N/A changed from the prior year.
  • EBIT Margin hit 114.97% in Q3 2025 for Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
  • Across five years, EBIT Margin topped out at 27.8% in Q4 2024 and bottomed at 21604.84% in Q1 2021.
  • Average EBIT Margin over 4 years is 3505.29%, with a median of 1798.77% recorded in 2025.
  • Year-over-year, EBIT Margin tumbled -1957437bps in 2021 and then surged 1977868bps in 2022.
  • Cyclerion Therapeutics' EBIT Margin stood at 2690.06% in 2021, then plummeted by -63bps to 4389.87% in 2022, then skyrocketed by 101bps to 27.8% in 2024, then tumbled by -514bps to 114.97% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 114.97%, 1797.85%, and 1798.77% for Q3 2025, Q2 2025, and Q1 2025 respectively.